Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Trkola

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Journal of Virology|June 1, 1994
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAST Muster, R Guinea, A Trkola, et al.
Journal of Virology|December 16, 1998
Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusionC J Gordon, M A Muesing, A E Proudfoot, et al.
Journal of Virology|July 10, 1999
The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivityA Trkola, C Gordon, J Matthews, et al.
AIDS Research and Human Retroviruses|December 1, 1994
A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1M Purtscher, A Trkola, G Gruber, et al.
Journal of Virology|November 13, 1998
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1P W Parren, M Wang, A Trkola, et al.
AIDS Research and Human Retroviruses|April 1, 1994
Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalizationA Buchacher, R Predl, K Strutzenberger, et al.
AIDS (London, England)|June 1, 1996
Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5M Purtscher, A Trkola, A Grassauer, et al.
Journal of Virology|February 1, 1996
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1A Trkola, M Purtscher, T Muster, et al.
The Journal of Infectious Diseases|August 19, 2000
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infectionJ M Binley, A Trkola, T Ketas, et al.
Journal of Virology|November 1, 1995
Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virusT Muster, B Ferko, A Klima, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Journal of Virology|June 1, 1994
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAST Muster, R Guinea, A Trkola, et al.
Journal of Virology|December 16, 1998
Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusionC J Gordon, M A Muesing, A E Proudfoot, et al.
Journal of Virology|July 10, 1999
The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivityA Trkola, C Gordon, J Matthews, et al.
AIDS Research and Human Retroviruses|December 1, 1994
A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1M Purtscher, A Trkola, G Gruber, et al.
Journal of Virology|November 13, 1998
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1P W Parren, M Wang, A Trkola, et al.
AIDS Research and Human Retroviruses|April 1, 1994
Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalizationA Buchacher, R Predl, K Strutzenberger, et al.
AIDS (London, England)|June 1, 1996
Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5M Purtscher, A Trkola, A Grassauer, et al.
Journal of Virology|February 1, 1996
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1A Trkola, M Purtscher, T Muster, et al.
The Journal of Infectious Diseases|August 19, 2000
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infectionJ M Binley, A Trkola, T Ketas, et al.
Journal of Virology|November 1, 1995
Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virusT Muster, B Ferko, A Klima, et al.
Pageof 5